
Shares of biotech firm Virpax Pharmaceuticals VRPX.O fall 55.2% to 54 cents
VRPX's stock to be delisted from Nasdaq tomorrow for failing to meet minimum stockholders' equity requirement - SEC filing
Co does not plan to appeal the delisting decision
Three board members and CFO, Usama Chaudhry, have resigned from their positions, effective immediately
Including session's move, stock down 94% YTD